Lucite deal toy commemorating financing provided to ITM, a Munich-based biotech company. (25ALJ200)
Lucite deal toy commemorating financing provided to ITM, a Munich-based biotech company. (25ALJ200)
Crystal financial tombstone marking a public offering by Cellectar Biosciences. The New Jersey-based company will use the proceeds to fund a clinical study of a breast cancer drug. (25AKL244)
Custom crystal commemorating FDA approval of Gomekli, a treatment for the rare tumor disease ncurofibromatosis 1 (NF1). (25AZH094)
Crystal deal toy commemorating a follow-on stock offering by Oculis. The Swiss biopharmaceutical company provides treatment for eye conditions such as diabetic macula edema and acute optic neuritis. (25AKL187)
Custom Lucite, incorporating an embedded vial, celebrating the first-in-human dosing in a Phase 1 clinical trial of cancer treatment developed by biotech company Immunome. (25ALJ040)
Custom Lucite celebrating the approval by the U.S. Food and Drug Administration (FDA) of the drug Crenessity. Crenessity was developed by Neurocrine Biosciences to treat a rare congenital adrenal condition. (25ALJ020)
Logo-themed crystal financial tombstone commemorating a follow-on stock offering by Palisade Bio. The biopharmaceutical firm is based in Carlsbad, California. (25AKL019)
Custom crystal deal toy marking an investment in GXP-Storage. The Raleigh, North Carolina-based company provides storage for materials for life sciences and biomedical research. (25AZH003)
Custom Lucite deal toy, replicating a spray bottle product, commemorating a follow-on stock offering by Novabay Pharmaceuticals. The Emeryville, California-based biopharmaceutical company develops products for the eye care market. (24AKL343)
